###begin article-title 0
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 23 30 23 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 57 62 <span type="species:ncbi:9606">human</span>
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells
###end article-title 0
###begin p 1
###xml 38 56 38 56 <email xmlns:xlink="http://www.w3.org/1999/xlink">casanova@necker.fr</email>
CORRESPONDENCE Jean-Laurent Casanova: casanova@necker.fr
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 499 504 496 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFB1</italic>
###xml 506 512 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1</italic>
###xml 518 524 515 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR2</italic>
###xml 614 619 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRAK4</italic>
###xml 624 629 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYD88</italic>
###xml 760 765 757 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 861 866 858 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 871 878 868 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 186 191 <span type="species:ncbi:9606">human</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 1110 1115 <span type="species:ncbi:9606">human</span>
The cytokines controlling the development of human interleukin (IL) 17-producing T helper cells in vitro have been difficult to identify. We addressed the question of the development of human IL-17-producing T helper cells in vivo by quantifying the production and secretion of IL-17 by fresh T cells ex vivo, and by T cell blasts expanded in vitro from patients with particular genetic traits affecting transforming growth factor (TGF) beta, IL-1, IL-6, or IL-23 responses. Activating mutations in TGFB1, TGFBR1, and TGFBR2 (Camurati-Engelmann disease and Marfan-like syndromes) and loss-of-function mutations in IRAK4 and MYD88 (Mendelian predisposition to pyogenic bacterial infections) had no detectable impact. In contrast, dominant-negative mutations in STAT3 (autosomal-dominant hyperimmunoglobulin E syndrome) and, to a lesser extent, null mutations in IL12B and IL12RB1 (Mendelian susceptibility to mycobacterial diseases) impaired the development of IL-17-producing T cells. These data suggest that IL-12Rbeta1- and STAT-3-dependent signals play a key role in the differentiation and/or expansion of human IL-17-producing T cell populations in vivo.
###end p 3
###begin p 4
###xml 238 239 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 425 426 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 1233 1234 1203 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 418 423 <span type="species:ncbi:10090">mouse</span>
###xml 533 538 <span type="species:ncbi:10090">mouse</span>
###xml 631 636 <span type="species:ncbi:10090">mouse</span>
IL-17A (IL-17) is the first of a six-member family of cytokines (IL-17A-F). IL-17 is produced by NK and T cell subsets, including helper alpha/beta T cells, gamma/delta T cells, and NKT cells, and it binds to a widely expressed receptor (1). This cytokine was first described 10 yr ago, but interest in this molecule was recently revived by the identification of a specific IL-17-producing T helper cell subset in the mouse (1). The specific development and phenotype of IL-17-producing helper T cells have been characterized in the mouse model, in which these cells have clearly been identified as a Th17 subset. The hallmarks of mouse Th17 cells include (a) a pattern of cytokine production different from those of the Th1 and Th2 subsets, with high levels of IL-17 production, often accompanied by IL-17F and IL-22; (b) dependence on TGF-beta and IL-6 for early differentiation from naive CD4 T cells, followed by dependence on IL-21 and IL-23 for further expansion; and (c) dependence on at least four transcription factors for differentiation: the Th17-specific retinoic acid receptor-related orphan receptor gammat (RORgammat) and RORalpha, and the more promiscuous STAT-3 and IFN regulatory factor 4 (for review see reference 1).
###end p 4
###begin p 5
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 617 618 614 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 619 620 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 692 693 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 695 696 689 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 698 699 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 736 737 730 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 770 771 764 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 773 774 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 776 777 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 874 875 868 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 876 877 870 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 947 948 938 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 950 951 941 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 1027 1028 1018 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1172 1174 1160 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1175 1177 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 210 215 <span type="species:ncbi:9606">human</span>
###xml 262 267 <span type="species:ncbi:9606">human</span>
###xml 538 543 <span type="species:ncbi:9606">human</span>
###xml 1336 1341 <span type="species:ncbi:9606">human</span>
###xml 1376 1380 <span type="species:ncbi:10090">mice</span>
Increasingly detailed descriptions of the in vitro and in vivo differentiation of the Th17 subset in mice are becoming available. In contrast, the tremendous, uncontrolled genetic and epigenetic variability of human samples has made it difficult to characterize human IL-17-producing T cells (2-13). It has proved very difficult to identify the cytokines governing the differentiation of these cells in vitro. The first four groups that have investigated this issue all suggested that TGF-beta was not required for the differentiation of human IL-17-producing T helper cells from purified naive CD4 T cells in vitro (5-8). TGF-beta was even found to inhibit differentiation in three studies (5, 6, 8). IL-6 was inhibitory in one study (6) and redundant in three others (5, 7, 8). In contrast, IL-23 was found to enhance the development of IL-17 T cells in all four studies (5-8) and IL-1beta was identified as a positive regulator in two studies (5, 6), whereas IL-21, which was tested in one study, was found to be redundant (8). In contrast, three recent studies showed that TGF-beta is essential in this process, whereas there was more redundancy between the four ILs (11-13). In vitro studies using recombinant cytokines and blocking antibodies have therefore yielded apparently conflicting results, particularly if the results for human cells are compared with those for mice.
###end p 5
###begin p 6
###xml 481 486 475 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFB1</italic>
###xml 488 490 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 537 543 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1</italic>
###xml 547 553 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR2</italic>
###xml 555 557 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 668 673 662 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRAK4</italic>
###xml 675 677 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 682 687 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYD88</italic>
###xml 932 937 923 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 939 941 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 943 945 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 1130 1135 1121 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 1139 1146 1130 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 1148 1150 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1442 1444 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
###xml 823 831 <span type="species:ncbi:9606">patients</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
We used a novel approach to address this issue, making use of patients with various inborn errors of immunity impairing most of these cytokine signaling pathways separately to investigate the development of IL-17 T cells in vivo. We studied the following groups: (a) patients with autosomal-dominant developmental disorders associated with various mutations in the TGF-beta pathway associated with enhanced TGF-beta signaling, such as Camurati-Engelmann disease, with mutations in TGFB1 (14), or Marfan-like syndromes, with mutations in TGFBR1 or TGFBR2 (15); (b) patients with autosomal-recessive susceptibility to pyogenic bacteria and loss-of-function mutations in IRAK4 (16) or MYD88 (unpublished data), whose cells do not respond to IL-1beta and related cytokines or to Toll-like receptors (TLRs) other than TLR3; (c) patients with autosomal-dominant hyper-IgE syndrome (AD-HIES) associated with dominant-negative mutations in STAT3 (17, 18), whose cells respond poorly to several cytokines, including IL-6; and (d) patients with autosomal-recessive susceptibility to mycobacterial diseases and loss-of-function mutations in IL12B or IL12RB1 (19), whose cells do not express or do not respond to IL-12 and IL-23 (Table S1, available at ). The role of IL-21 cannot be studied in this way, as the only known defects in this pathway (i.e., JAK3 and common gamma chain deficiencies) are typically associated with a total absence of T cells (20).
###end p 6
###begin title 7
RESULTS AND DISCUSSION
###end title 7
###begin p 8
###xml 383 398 383 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 848 853 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRAK4</italic>
###xml 857 862 857 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYD88</italic>
###xml 1159 1174 1156 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 1227 1232 1224 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 1236 1243 1233 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 1278 1283 1275 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 1319 1326 1316 1323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 1480 1482 1477 1479 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 1484 1499 1481 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 1667 1672 1661 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFB1</italic>
###xml 1676 1682 1670 1676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR2</italic>
###xml 1727 1735 1721 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 816 824 <span type="species:ncbi:9606">patients</span>
###xml 1195 1203 <span type="species:ncbi:9606">patients</span>
###xml 1433 1441 <span type="species:ncbi:9606">patients</span>
###xml 1516 1524 <span type="species:ncbi:9606">patients</span>
###xml 1596 1604 <span type="species:ncbi:9606">patients</span>
We used flow cytometry to investigate the percentage of IL-17-expressing blood T cells ex vivo in 49 healthy controls. Nonadherent PBMCs were stained for CD3, CD4, CD8, and IL-17. No IL-17-producing T cells were detected in the absence of activation (unpublished data). Upon activation with PMA-ionomycin, the percentage of CD3-positive cells producing IL-17 ranged from 0.06 to 2% (Fig. 1, A and B). The vast majority (>90%) of IL-17-positive cells were CD4-positive and CD8-negative (unpublished data). Thus, within the general population, there is considerable interindividual variability in the numbers of IL-17-producing cells present among freshly isolated T cells activated ex vivo. This makes it difficult to assess the impact of genetic lesions on the development of IL-17-producing T cells. We tested nine patients with null mutations in IRAK4 or MYD88, whose cells were unresponsive to IL-1beta (and most TLRs and other IL-1 cytokine family members). The proportion of IL-17-producing T cells was not significantly different from that in healthy controls, as shown by Wilcoxon tests comparing the values for each individual between the two groups (Fig. 1, A and B). We then tested 17 patients with null mutations in IL12B or IL12RB1, whose cells did not produce (for IL12B mutations) or did not respond (for IL12RB1 mutations) to IL-23 (and IL-12). Interestingly, there were clearly fewer IL-17-producing T cells in these patients than in healthy controls (P = 4.7 x 10-3; Fig. 1, A and B). However, some patients had normal numbers of IL-17-producing T cells. In contrast, cells from patients with mildly enhanced TGF-beta responses owing to mutations in TGFB1 or TGFBR2 did not differ significantly from controls (Fig. 1 B). These results suggest that IL-1R-associated kinase 4 (IRAK-4) and MyD88 are not required for the development of IL-17-producing T cells in vivo, that TGF-beta probably does not markedly inhibit this process, and that both IL-12p40 and IL-12Rbeta1 are required, at least in most individuals and in these experimental conditions of flow cytometry on T cells activated ex vivo.
###end p 8
###begin p 9
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of IL-17&#8211;producing T cells ex vivo.</bold>
###xml 727 728 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 766 771 763 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRAK4</italic>
###xml 775 780 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYD88</italic>
###xml 782 783 779 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 790 795 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 799 806 796 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 808 809 805 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 817 822 814 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFB1</italic>
###xml 826 832 823 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR2</italic>
###xml 834 835 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 846 851 843 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 853 854 850 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 195 202 <span type="species:ncbi:9606">patient</span>
###xml 234 241 <span type="species:ncbi:9606">patient</span>
###xml 272 279 <span type="species:ncbi:9606">patient</span>
###xml 619 626 <span type="species:ncbi:9606">patient</span>
###xml 739 747 <span type="species:ncbi:9606">patients</span>
Identification of IL-17-producing T cells ex vivo. (A) Flow cytometry analysis of CD3 and IL-17 in nonadherent PBMCs activated with PMA-ionomycin as a representative control, an IRAK-4-deficient patient (P4), an IL-12Rbeta1-deficient patient (P17), and a STAT-3-deficient patient (P36; Table S1, available at ). The percentage indicated in the gate is that of IL-17- and CD3-positive cells. (B) Percentage of CD3-positive cells that were also IL-17-positive, as determined by flow cytometry of nonadherent PBMCs activated with PMA-ionomycin. Each symbol represents a value from an individual control (black circles) or patient (red circles). Horizontal bars represent medians. The p-values for Wilcoxon tests between controls (n = 49) and patients with mutations in IRAK4 or MYD88 (n = 9), IL12B or IL12RB1 (n = 17), TGFB1 or TGFBR2 (n = 7), and STAT3 (n = 16) are indicated.
###end p 9
###begin p 10
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 319 321 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 323 338 323 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1, A and B</xref>
###xml 1009 1010 1006 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 1024 1025 1021 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1027 1028 1024 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 1096 1097 1089 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 1121 1123 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1287 1288 1280 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">,</italic>
###xml 1530 1535 1515 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRAK4</italic>
###xml 1540 1545 1525 1530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYD88</italic>
###xml 1559 1561 1544 1546 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 1564 1571 1549 1556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 1576 1581 1561 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 1595 1597 1580 1582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 1603 1608 1588 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 1620 1622 1605 1607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 1663 1668 1648 1653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFB1</italic>
###xml 1672 1678 1657 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR2</italic>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
###xml 801 809 <span type="species:ncbi:9606">patients</span>
###xml 915 923 <span type="species:ncbi:9606">patients</span>
###xml 1003 1007 <span type="species:ncbi:10090">mice</span>
###xml 1016 1022 <span type="species:ncbi:9606">humans</span>
###xml 1089 1094 <span type="species:ncbi:10090">mouse</span>
###xml 1103 1108 <span type="species:ncbi:9606">human</span>
###xml 1250 1255 <span type="species:ncbi:9606">human</span>
###xml 1412 1420 <span type="species:ncbi:9606">patients</span>
###xml 1503 1511 <span type="species:ncbi:9606">patients</span>
###xml 1636 1644 <span type="species:ncbi:9606">patients</span>
We tested 16 patients with AD-HIES bearing mutations in STAT3. They displayed normal proportions of CCR6-positive CCR4-positive CD4 T cells but low proportions of CCR6-positive CCR4-negative CD4 T cells (Table S2, available at ). These patients had significantly fewer IL-17-positive T cells than controls (P = 9.7 x 10-7; Fig. 1, A and B). However, as observed in patients with IL-12p40 or IL-12Rbeta1 deficiency, some AD-HIES patients had normal proportions of IL-17-producing T cells, perhaps reflecting genetic or epigenetic heterogeneity between individuals, residual STAT-3 signaling, or both. In these experimental conditions, the huge variations in IL-17 secretion between healthy controls (from 50 to 5,000 pg/ml), as measured by ELISA, prevented rigorous comparison with the small number of patients studied (unpublished data). We did not assess other potential features of IL-17-producing T cells in the patients studied, such as the production of IL-22, a cytokine produced by Th17 cells in mice (1) and humans (5, 6), or expression of RORgammat, a key transcription factor in mouse (1) and human Th17 cells (11), as too few blood samples were available. Our results nonetheless suggest that STAT-3 is required for the differentiation of human IL-17-producing T cells in vivo, as suggested by flow cytometry analysis on ex vivo-activated T cells. We also assessed the production of IFN-gamma in some patients (Fig. S1). The proportion of IFN-gamma-producing T cells was found to be lower in patients with mutations in IRAK4 and MYD88 (P = 1.2 x 10-4), IL12RB1 and IL12B (P = 1.8 x 10-3), or STAT3 (P = 8 x 10-4), but not in patients with mutations in TGFB1 or TGFBR2 (P = 0.11).
###end p 10
###begin p 11
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1292 1300 1286 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1434 1436 1428 1430 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 1551 1552 1539 1540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1560 1566 1548 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 1742 1743 1727 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 1757 1759 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1760 1762 1745 1747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 79 84 <span type="species:ncbi:9606">human</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 386 391 <span type="species:ncbi:10090">mouse</span>
###xml 489 497 <span type="species:ncbi:9606">patients</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
###xml 1736 1740 <span type="species:ncbi:10090">mice</span>
###xml 1749 1755 <span type="species:ncbi:9606">humans</span>
No consensus has yet been reached on how to best induce the differentiation of human IL-17 T cells from naive CD4 precursors in vitro (5-8, 11-13), and only small amounts of blood from a limited number of blood samples from our patients were available. We therefore tried to induce specific IL-17 memory T cell responses using the cytokines shown to be critical for this lineage in the mouse. We evaluated IL-17 production by populations of T cell blasts expanded in vitro from PBMCs. All patients studied, in particular STAT-3-deficient patients, displayed normal proportions of CD4 and CD8 T cells (Table S3, available at ). We incubated nonadherent PBMCs from controls with OKT3 for 5 d, alone or in the presence of IL-23, IL-1beta, TGF-beta, or IL-6, or a combination of these four cytokines, and then activated them with PMA-ionomycin. We did not assess the development of antigen-specific IL-17-producing T cells. There were no IL-17-positive T cells in any control or in any set of experimental conditions in the absence of activation with PMA-ionomycin, as shown by flow cytometry (unpublished data). In the absence of cytokine stimulation, the percentage of IL-17-positive T cells found in healthy controls after stimulation with PMA-ionomycin was highly variable (from 0.12 to 10%; Fig. 2 A). A statistically significant increase in the number of IL-17-producing T cells was observed after stimulation with IL-23 (P = 7 x 10-3) and IL-1beta (P = 0.04), but not after stimulation with TGF-beta (P = 0.1) or IL-6 (P = 0.3), as shown by paired t tests (Fig. 2 and not depicted). This recall-response pattern is consistent with IL-1beta and IL-23 playing an important role in maintaining and expanding IL-17 T cell populations in mice (1) and humans (11-13).
###end p 11
###begin p 12
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Identification of IL-17&#8211;expressing T cell blasts expanded in vitro.</bold>
###xml 756 761 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 862 875 850 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B-IL12RB1</italic>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 454 461 <span type="species:ncbi:9606">patient</span>
###xml 658 665 <span type="species:ncbi:9606">patient</span>
###xml 725 733 <span type="species:ncbi:9606">patients</span>
###xml 939 947 <span type="species:ncbi:9606">patients</span>
Identification of IL-17-expressing T cell blasts expanded in vitro. Intracellular production of IL-17 in T cell blasts activated with PMA-ionomycin for controls (black circles) and patients (red circles), as assessed by flow cytometry. The cells were cultured in different stimulation conditions: OKT3 only (A), or OKT3 with IL-23 (B), IL-1beta (C), or IL-23, IL-1beta, TGF-beta, and IL-6 (D). Each symbol represents a value for an individual control or patient. Horizontal bars represent medians. In controls, stimulation with IL-23 and IL-1beta had a significant effect with respect to medium alone (P < 0.05). The p-values for Wilcoxon tests between each patient group and the control group are indicated. In B and D, the patients circled in blue carry IL12B mutations and cannot produce IL-12 and IL-23, but can respond to both cytokines. The p-value of the IL12B-IL12RB1 group was therefore calculated only with IL-12Rbeta1-deficient patients (*).
###end p 12
###begin p 13
###xml 334 340 328 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 370 371 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 393 394 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 533 535 524 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 537 545 528 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 638 640 626 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 694 702 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1111 1117 1096 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 346 354 <span type="species:ncbi:9606">patients</span>
###xml 575 583 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 834 842 <span type="species:ncbi:9606">patients</span>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
We then investigated IL-17 production by T cell blasts from various patients in the same experimental conditions. For four patients with IRAK-4 or MyD88 deficiency and impaired responses to IL-1beta, the proportion of IL-17-producing cells appeared to be normal in the various experimental conditions, except in response to IL-1beta (Fig. 2). 16 patients with IL-12p40 (n = 2) or IL-12Rbeta1 (n = 14) deficiency were found to have much smaller proportions of IL-17-producing T cells in the absence of cytokine stimulation (P = 7 x 10-5; Fig. 2 A). The two IL-12p40-deficient patients, unlike the IL-12Rbeta1-deficient patients (P = 5 x 10-5), apparently responded to IL-23 in these conditions (Fig. 2 B). These data suggest that IL-23 makes a major contribution to the expansion of the IL-17 T cell population in this assay. However, patients bearing specific IL-23(R) mutations would be required to rigorously test this hypothesis. We then tested seven patients with mutations associated with mildly enhanced TGF-beta responses and found no significant differences from controls in the four conditions tested (Fig. 2).
###end p 13
###begin p 14
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 160 162 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 172 174 172 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 188 190 188 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 206 212 206 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
###xml 508 513 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 757 765 <span type="species:ncbi:9606">patients</span>
In contrast, 14 patients with mutations in STAT3 had almost no detectable IL-17-producing T cells in any of the four conditions tested (P = 3.2 x 10-8, 4.9 x 10-9, 1.9 x 10-9, and 3.6 x 10-9, respectively; Fig. 2). This phenotype was clearly more pronounced than that observed with cells from IL-12p40- and IL-12Rbeta1-deficient patients, as the almost complete lack of IL-17-positive T cells was not complemented by IL-23, IL-1beta, or a combination of the four cytokines. T cells from the 11 patients with STAT3 mutations studied proliferated normally in these conditions. Our results demonstrate that STAT-3 is required for the expansion of IL-17-producing T cell blasts, at least in these experimental conditions. In these conditions, all the groups of patients studied had fewer IFN-gamma-producing cells than controls (Fig. S2, available at ).
###end p 14
###begin p 15
###xml 180 186 176 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 395 403 389 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 471 473 465 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 845 847 828 830 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 858 860 841 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 872 874 855 857 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 890 901 873 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3, B&#8211;D</xref>
###xml 1216 1218 1196 1198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 1222 1224 1202 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 1228 1230 1208 1210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 1242 1244 1222 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 1260 1266 1240 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 1425 1431 1402 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 1020 1028 <span type="species:ncbi:9606">patients</span>
###xml 1593 1601 <span type="species:ncbi:9606">patients</span>
Finally, we assessed the secretion of IL-17, IL-22, and IFN-gamma by T cell blasts from controls and patients, with or without activation with PMA-ionomycin, as measured by ELISA (Fig. 3; and Figs. S3 and S4, available at ). Control T cell blasts cultured without recombinant cytokine produced detectable amounts of IL-17 in the absence of activation by PMA-ionomycin (mean = 137 +/- 149 pg/ml; Fig. 3 A). The amounts of IL-17 secreted increased significantly (P = 3 x 10-4) upon activation with PMA-ionomycin (mean = 7,338 +/- 11,134 pg/ml). However, considerable interindividual variability was observed in both sets of experimental conditions. The addition of IL-23, IL-1beta, or a combination of IL-23, IL-1beta, TGF-beta, and IL-6 significantly increased the amounts of secreted IL-17 in the absence of activation with PMA-ionomycin (P = 10-4 and 8 x 10-4, and P < 10-4, respectively; Fig. 3, B-D). Upon PMA-ionomycin activation, only IL-1beta significantly increased the amount of IL-17 secretion (P = 0.04). Four patients with IRAK-4 or MyD88 deficiency were tested. They displayed low levels of IL-17 secretion in the absence of activation with PMA-ionomycin in the four sets of conditions tested (P = 4 x 10-3, 10-5, 10-4, and 8 x 10-4, respectively; Fig. 3). Upon PMA-ionomycin activation, the level of IL-17 secretion is not significantly different from the controls, except in the presence of IL-1beta (P = 0.04; Fig. 3). These results suggest that the Toll/IL-1R signaling pathway, and possibly the IL-1R pathway, may be involved in the secretion of IL-17 in T cell blasts. These patients produced amounts of IL-22 that were similar to the controls (Fig. S3).
###end p 15
###begin p 16
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IL-17 secretion by T cell blasts expanded in vitro.</bold>
###xml 750 755 741 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 857 870 848 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B-IL12RB1</italic>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 601 608 <span type="species:ncbi:9606">patient</span>
###xml 719 727 <span type="species:ncbi:9606">patients</span>
###xml 935 943 <span type="species:ncbi:9606">patients</span>
IL-17 secretion by T cell blasts expanded in vitro. Secretion of IL-17 by T cell blasts from controls (black circles) and patients (red circles), as measured by ELISA. Open circles represent values in the absence of stimulation, and closed circles correspond to values obtained after stimulation with PMA-ionomycin. Different stimulation conditions are shown: OKT3 only (A), or OKT3 with IL-23 (B), IL-1beta (C), or IL-23, IL-1beta, TGF-beta, and IL-6 (D). Each symbol corresponds to a value obtained from an individual. Horizontal bars represent medians. The p-values for Wilcoxon tests between each patient group and the control group, either unstimulated or stimulated with PMA-ionomycin, are indicated. In B and D, patients circled in blue carry IL12B mutations and cannot produce IL-12 and IL-23, but can respond to both cytokines. The p-values of the IL12B-IL12RB1 group were therefore calculated only with IL-12Rbeta1-deficient patients (*).
###end p 16
###begin p 17
###xml 150 158 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 246 254 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 C</xref>
###xml 392 394 383 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 411 413 402 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;3</sup>
###xml 442 450 433 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 D</xref>
###xml 505 510 496 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 515 522 506 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 801 803 789 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 811 813 799 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 821 824 809 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;11</sup>
###xml 832 834 820 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 838 840 826 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 848 850 836 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 858 860 846 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 872 874 860 862 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 932 938 920 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 296 304 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 606 614 <span type="species:ncbi:9606">patients</span>
###xml 719 727 <span type="species:ncbi:9606">patients</span>
###xml 1050 1055 <span type="species:ncbi:9606">human</span>
###xml 1104 1109 <span type="species:ncbi:9606">human</span>
T cell blasts from the 13 IL-12p40- or IL-12Rbeta1-deficient patients tested secreted normal amounts of IL-17 in the absence of cytokine stimulation (Fig. 3 A). The 10 patients tested produced normal amounts of IL-17 in the presence of IL-1beta (Fig. 3 C). In the presence of the four cytokines, patients with IL-12Rbeta1 deficiency did not secrete normal amounts of IL-17 without (P = 2 x 10-3) or with (P = 10-3) PMA-ionomycin stimulation (Fig. 3 D). In all culture conditions, cells from patients with IL12B and IL12RB1 mutations secreted less IL-22 than control cells (Fig. S3). T cell blasts from all patients with mutations in the TGF-beta pathway secreted normal amounts of IL-17, whereas T cell blasts from all patients with STAT-3 deficiency secreted much smaller amounts of IL-17 (P = 8 x 10-6, 9 x 10-7, 9 x 10-11, 2 x 10-7, 10-8, 3 x 10-7, 4 x 10-9, and 3 x 10-6, respectively) and IL-22 in all experimental conditions (Fig. 3 and Fig. S3). These data indicate that STAT-3 is required for the maintenance and expansion of IL-17-secreting human T cell blasts and for the secretion of IL-22 by human T cell blasts, at least in these experimental conditions.
###end p 17
###begin p 18
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 839 840 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 961 962 958 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 964 966 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 968 970 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1063 1064 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1065 1066 1062 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1068 1070 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1071 1073 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1315 1316 1309 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1318 1319 1312 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 1376 1377 1370 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 1519 1520 1510 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 1521 1522 1512 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1626 1627 1614 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 295 301 <span type="species:ncbi:9606">humans</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
###xml 871 876 <span type="species:ncbi:10090">mouse</span>
###xml 1006 1011 <span type="species:ncbi:9606">human</span>
###xml 1284 1289 <span type="species:ncbi:9606">human</span>
###xml 1370 1374 <span type="species:ncbi:10090">mice</span>
###xml 1488 1493 <span type="species:ncbi:9606">human</span>
###xml 1576 1584 <span type="species:ncbi:9606">patients</span>
Patients with STAT-3 deficiency had the most severe IL-17 phenotype of all the patients tested, with a profound impairment of IL-17 production by T cells ex vivo and T cell blasts in vitro. This observation is consistent with findings for STAT-3-deficient mice (1, 21-24) and a recent report in humans (25). Impaired IL-6 signaling may be the key factor involved, as suggested by the results obtained for IL-6-deficient mice (1, 26, 27). However, STAT-3 is also involved in other relevant pathways, including the IL-21 and IL-23 pathways. Our data for IL-12p40- and IL-12Rbeta1-deficient cells suggest that IL-23 is required for the optimal development of IL-17-producing T cells. IL-23 is probably the only cytokine involved, as the patients also lacked IL-12 responses, which might be expected to enhance the development of this subset (1). This is consistent with the mouse model, in which IL-23 is required for the maintenance and expansion of these cells (1, 28, 29), and with the results of previous human studies based on the use of recombinant cytokines (5-8, 11-13). In contrast, our findings for IRAK-4- and MyD88-deficient cells do not support the notion that IL-1beta (or any of the IL-1Rs and TLRs other than, possibly, TLR3 and TLR4) is essential for the development of human IL-17-producing T cells (5, 6), consistent with the phenotype of IL-1-deficient mice (1). Finally, the paradoxical suggestion that TGF-beta may have no effect or may even inhibit the development of human IL-17-producing T cells (5-8) was neither supported nor disproved by our data for patients with mildly enhanced TGF-beta responses (1).
###end p 18
###begin p 19
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 199 209 199 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Klebsiella</italic>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib31">31</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 362 372 355 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Klebsiella</italic>
###xml 451 461 444 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella</italic>
###xml 463 465 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 485 495 478 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Klebsiella</italic>
###xml 500 510 493 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella</italic>
###xml 676 678 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 680 682 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 743 750 736 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 752 754 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 755 757 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 949 956 939 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Candida</italic>
###xml 958 960 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1298 1300 1281 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 1302 1304 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 1435 1449 1418 1432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus</italic>
###xml 1451 1453 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 1541 1555 1521 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus</italic>
###xml 1779 1781 1759 1761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 1783 1785 1763 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 89 94 <span type="species:ncbi:10090">mouse</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 685 689 <span type="species:ncbi:10090">Mice</span>
###xml 842 850 <span type="species:ncbi:9606">patients</span>
###xml 917 925 <span type="species:ncbi:9606">patients</span>
###xml 1086 1094 <span type="species:ncbi:9606">patients</span>
###xml 1143 1151 <span type="species:ncbi:9606">patients</span>
###xml 1258 1263 <span type="species:ncbi:10090">mouse</span>
###xml 1377 1385 <span type="species:ncbi:9606">patients</span>
###xml 1387 1392 <span type="species:ncbi:10090">Mouse</span>
###xml 1435 1449 <span type="species:ncbi:1280">Staphylococcus</span>
###xml 1506 1514 <span type="species:ncbi:9606">patients</span>
###xml 1541 1555 <span type="species:ncbi:1280">Staphylococcus</span>
###xml 1573 1578 <span type="species:ncbi:9606">human</span>
###xml 1676 1681 <span type="species:ncbi:9606">human</span>
Does our report provide any clues to the possible function of IL-17 in host defense? The mouse Th17 subset plays a key role in mucosal defense (30). IL-23- and IL-17-deficient mice are vulnerable to Klebsiella (31, 32). This may account for the greater susceptibility of IL-12p40- and IL-12Rbeta1-deficient patients than of IFN-gammaR-deficient patients to both Klebsiella (Levin, M., and S. Pedraza, personal communication; Table S1) and the related Salmonella (19). However, neither Klebsiella nor Salmonella is commonly found as a pathogen in STAT-3-deficient patients despite the apparently greater defect of these patients in terms of IL-17-producing T cell development (17, 18). Mice with impaired IL-17 immunity are also susceptible to Candida (33-35). This may account for the peripheral candidiasis commonly seen in STAT-3-deficient patients. Interestingly, although most IL-12p40- and IL-12Rbeta1-deficient patients are not susceptible to Candida (19), some present with peripheral candidiasis (unpublished data). Mycobacterial disease is exceedingly rare in STAT-3-deficient patients, but not in IL-12p40- and IL-12Rbeta1-deficient patients, in whom it results from impaired IFN-gamma immunity, which is consistent with the redundancy of IL-17 in mouse primary immunity to mycobacteria (36, 37). Staphylococcal disease is the main infection seen in STAT-3-deficient patients. Mouse IL-17 seems to be involved in immunity to Staphylococcus (38). However, both IL-12p40- and IL-12Rbeta1-deficient patients are normally resistant to Staphylococcus. The function of human IL-17 and related cytokines in host defense therefore remains unknown. The genetic dissection of human infectious diseases should help us to attribute a function to this important cytokine in natura (39, 40).
###end p 19
###begin title 20
MATERIALS AND METHODS
###end title 20
###begin title 21
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls.
###end title 21
###begin p 22
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRAK4</italic>
###xml 253 258 253 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYD88</italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 267 274 267 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12RB1</italic>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFB1</italic>
###xml 283 289 283 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR1</italic>
###xml 291 297 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFBR2</italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT3</italic>
###xml 149 155 <span type="species:ncbi:9103">Turkey</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 430 437 <span type="species:ncbi:9606">patient</span>
###xml 445 452 <span type="species:ncbi:9606">patient</span>
55 healthy, unrelated individuals of various ages from 12 countries (Argentina, Canada, Cuba, France, Germany, Israel, Portugal, Spain, Switzerland, Turkey, UK, and USA) were tested as controls. We also investigated 50 patients with mutations in IRAK4, MYD88, IL12B, IL12RB1, TGFB1, TGFBR1, TGFBR2, or STAT3 (Table S1). Our study was conducted in accordance with the Helsinki Declaration, with informed consent obtained from each patient or the patient's family, as requested and approved by the institutional review board of the Necker Medical School.
###end p 22
###begin title 23
Purification and activation of nonadherent PBMCs.
###end title 23
###begin p 24
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 313 314 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 457 458 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 498 499 492 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 590 592 584 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 795 796 782 783 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 866 867 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1003 1005 989 991 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 1122 1123 1102 1103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
PBMCs were purified by centrifugation on a gradient (Ficoll-Paque PLUS; GE Healthcare) and resuspended in 10% FBS in RPMI (RPMI-10% FBS; Invitrogen). Adherent monocytes were removed by plating PBMCs in a 75-cm2 horizontal culture flask and incubating them for 2-3 h at 37degreesC in an atmosphere containing 5% CO2. The nonadherent cells were washed in RPMI and counted with a counter (Vi-Cell XR; Beckman Coulter). For flow cytometry, we distributed 5 x 106 cells in 5 ml RPMI-10% FBS in two 25-cm2 vertical culture flasks. One flask was stimulated with 40 ng/ml PMA (Sigma-Aldrich) and 10-5 M ionomycin (Sigma-Aldrich). All cells were treated with 1 mul/ml Golgiplug (BD Biosciences), a secretion inhibitor. The flasks were incubated for 12 h at 37degreesC under an atmosphere containing 5% CO2. For ELISA, a 200-mul aliquot of cells at a concentration of 2.5 x 106 cells/ml in RPMI-10% FBS was dispensed into each well of a 96-well plate. The cells were or were not activated with 40 ng/ml PMA and 10-5 M ionomycin. Supernatants were collected after 48 h of incubation at 37degreesC under an atmosphere containing 5% CO2.
###end p 24
###begin title 25
Expansion and activation of T cell blasts.
###end title 25
###begin p 26
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 498 499 485 486 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1006 1008 993 995 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 1095 1096 1075 1076 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1439 1441 1418 1420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 1579 1580 1552 1553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Nonadherent PBMCs were dispensed into 24-well plates at a density of 2.5 x 106 cells/ml in RPMI-10% FBS. All cells were activated with 2 mug/ml of an antibody against CD3 (Orthoclone OKT3; Janssen-Cilag) alone, or together with 5 ng/ml TGF-beta1 (240-B; R&D Systems), 20 ng/ml IL-23 (1290-IL; R&D Systems), 25 ng/ml IL-6 (206-IL; R&D Systems), 10 ng/ml IL-1beta (201-LB; R&D Systems), or combinations of these four cytokines. Plates were incubated at 37degreesC under an atmosphere containing 5% CO2 for 3 d. The cells in each well were restimulated using the same activation conditions, except that the antibody against CD3 was replaced by 40 IU/ml IL-2 (Proleukin i.v.; Chiron). 1 ml of each appropriate medium was added, and we gently passed the culture up and down through a pipette to break up clumps. The culture in each well was split in two. Flow cytometry was performed on one of the duplicate wells 2 d later. The cells in this well were stimulated by incubation for 12 h with 40 ng/ml PMA and 10-5 M ionomycin plus 1 mul/ml Golgiplug at 37degreesC under an atmosphere containing 5% CO2. FACS analysis was performed as described in the following section, without extracellular labeling. For ELISA analysis, cultures were allowed to differentiate under various conditions for 6 d and were then diluted 1:2 in RPMI-10% FBS supplemented with 40 IU/ml IL-2. 200 mul of cells in a 96-well plate were activated with 40 ng/ml PMA and 10-5 M ionomycin, or left unactivated. Supernatants were collected after 48 h of incubation at 37degreesC under an atmosphere containing 5% CO2.
###end p 26
###begin title 27
Flow cytometry.
###end title 27
###begin p 28
Cells were washed in cold PBS and dispensed into a 96-well plate for labeling. Extracellular labeling (for the ex vivo study only) was achieved by incubating the cells with 3 mul CD3-PECy5 in 50 mul PBS-2% FBS (BD Biosciences) for 20 min on ice. The cells were washed twice with cold PBS-2% FBS. They were fixed by incubation with 100 mul BD Cytofix (BD Biosciences) for 30 min on ice and washed twice with BD Cytoperm (BD Biosciences), with a 10-min incubation period in BD Cytoperm on ice for the first wash. Cells were then incubated for 1 h on ice with IL-17-Alexa Fluor 488 (eBioscience) or IFN-gamma-PE (BD Biosciences) at a dilution of 3 mul of antibody in 50 mul BD Cytoperm. Cells were washed twice with BD Cytoperm and analyzed with a FACScan machine and CellQuest software (both from Becton Dickinson).
###end p 28
###begin title 29
Determination of cytokine levels by ELISA.
###end title 29
###begin p 30
###xml 480 481 472 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 483 484 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 359 370 <span type="species:ncbi:3704">horseradish</span>
IL-17, IL-22, and IFN-gamma levels were determined by ELISA. We used the capture antibodies, detection antibodies, and standards supplied in the kits for IL-17 and IL-22 (Duoset; R&D Systems) and in the kit for IFN-gamma (Sanquin), diluted in HPE dilution buffer (Sanquin). Milk was used for blocking, and antibody binding was detected with streptavidin poly-horseradish peroxidase (Sanquin) and TMB microwell peroxidase substrate (KPL). The reaction was stopped by adding 1.8 M H2SO4. Optical density was determined with a microplate reader (MRX; Thermolab Systems).
###end p 30
###begin title 31
Statistical analysis.
###end title 31
###begin p 32
###xml 854 855 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 409 416 <span type="species:ncbi:9606">patient</span>
We first assessed differences between controls and patients (when there were more than two patients) for (a) the percentage of circulating IL-17-producing T cells, (b) the percentage of IL-17-positive T cells in vitro, and (c) the level of IL-17 production in various stimulation conditions, as assessed by ELISA. As the distribution of these three variables could not be assumed to be normal and some of the patient groups examined were very small, we used the nonparametric Wilcoxon exact test, as implemented in the NPAR1WAY module of SAS software (version 9.1; SAS Institute). A second set of tests was performed on controls only to assess the effects of different stimulation conditions on (a) the percentage of IL-17-positive T cells in vitro and (b) the level of IL-17 production, as assessed by ELISA. We used a strategy of matching, with paired t tests performed with the TTEST procedure of SAS software (version 9.1) to investigate the correlation between observations for different controls. For all analyses, P < 0.05 was considered statistically significant.
###end p 32
###begin title 33
Online supplemental material.
###end title 33
###begin p 34
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 441 449 <span type="species:ncbi:9606">patients</span>
###xml 583 591 <span type="species:ncbi:9606">patients</span>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
###xml 816 824 <span type="species:ncbi:9606">patients</span>
###xml 883 891 <span type="species:ncbi:9606">patients</span>
Fig. S1 shows the percentage of CD3-positive IFN-gamma-positive cells, as determined by flow cytometry of nonadherent PBMCs activated with PMA-ionomycin from controls and patients. Fig. S2 shows intracellular IFN-gamma production in T cell blasts activated with PMA-ionomycin from controls and patients in the various culture conditions, as assessed by flow cytometry. Fig. S3 shows the secretion of IL-22 by T cell blasts from controls and patients in the various culture conditions, as measured by ELISA. Fig. S4 shows the secretion of IFN-gamma by T cell blasts from controls and patients in the various culture conditions, as measured by ELISA. Table S1 shows the genetic and clinical features of the patients studied. Table S2 shows the proportions of CCR6-positive CD4 T cells in controls and STAT-3-deficient patients. Table S3 shows the proportions of CD4 and CD8 T cells in patients. Online supplemental material is available at .
###end p 34
###begin title 35
Supplementary Material
###end title 35
###begin title 36
[Supplemental Material Index]
###end title 36
###begin p 37
###xml 40 48 <span type="species:ncbi:9606">patients</span>
We would particularly like to thank the patients and their families, whose trust, support, and cooperation were essential for the collection of the data used in this study. We thank N. Matamoros, F.M. Ruemmele, and F. Rieux-Laucat for their help with this study, and all members of the laboratory for helpful discussions. We thank M. Courat, C. Bidalled, M. N'Guyen, T. Leclerc, S. Fahy, and G. Brami for secretarial and technical assistance.
###end p 37
###begin p 38
###xml 18 23 <span type="species:ncbi:9606">Human</span>
The Laboratory of Human Genetics of Infectious Diseases is supported by the Agence Nationale de la Recherche, the Programme Hospitalier de Recherche Clinique, the European Union (grant LHSP-CT-2005-018736), the BNP Paribas Foundation, the March of Dimes, the Dana Foundation, and the Candi'Oser Association. L. de Beaucoudrey is supported by the Fondation pour la Recherche Medicale as part of the PhD program of Pierre et Marie Curie University. J.L. Casanova is an International Scholar of the Howard Hughes Medical Institute.
###end p 38
###begin p 39
The authors have no conflicting financial interests.
###end p 39

